Comparison of single dose sodium valproate versus Dexamethasone Intravenously for treatment of acute migraine headache

Comparison of single dose sodium valproate (Depakine) versus Dexamethasone Intravenously for treatment of acute migraine headache

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014022116666N1

Enrollment

Registered

2014-06-22

Start date

2014-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headache. Migraine, unspecified

Interventions

Intervention 1: Control group: amp dexamethasome 8 mg interavenously. Intervention 2: Intervention: valproat Na(depakine) 400 mg intravenously.

Treatment - Drugs

Control group: amp dexamethasome 8 mg interavenously

Intervention: valproat Na(depakine) 400 mg intravenously

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 15-65 years old; acute migraine headache according to criteria IHS; duration lower than 48 hours; history of migraine headache from 6 month ago; no consumption NSAID from 24 hours ago and valproate Na as prophylaxis from 2 weeks ago. Exclusion criteria: pregnancy; breastfeeding; fever; allergy to drugs; peptic ulcer, GIB from 1 year ago; diabetes melitus and liver disorder and urea cycle defect.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Headache severity. Timepoint: 30 minutes, 1, 3, 6 and 24 hours after intervention. Method of measurement: Grading 1-4 and qualitative.	—

Secondary

Measure	Time frame
Photophobia. Timepoint: 1, 3, 6, 24 and 72 hours after intervention. Method of measurement: Questionnaire.;Vomiting. Timepoint: 1, 3, 6, 24 and 72 hours after intervention. Method of measurement: Questionnaire.;Phonophobia. Timepoint: 1,3,6,24,72 hours. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Karimi

Mazandaran University of Medical Sciences

n.karimi@mazums.ac.ir+98 15 1311 0714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026